News Gilead gains CAR-T approval, undercuts rival's headline pric... Cancer cell therapy approved for aggressive blood cancer
News BMS files Opdivo in post-surgery setting Opdivo performed better than BMS' Yervoy in clinical trial.
News AstraZeneca files Imfinzi for groundbreaking lung cancer use AZ also unveils promising results from early-stage lung cancer combination
Partner Content Partner Content ProQR Therapeutics: RNA Therapeutics for Patients with Cysti... RNA Therapeutics
News BMS scores an early victory in the new cancer biomarker batt... Bristol-Myers Squibb is hoping to drive forward its Opdivo cancer immunotherapy franchise by finding a better biomarker than PD-L1 - and has just produced encouraging results in a trial loo
News EU regulators back J&J's Zytiga in early prostate cancer use New use could give J&J drug edge over Pfizer's rival
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
